ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2256

Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study

Yasuo Kuroki1, Hiroshi Kaji2, Mika Yamauchi3 and Toshitsugu Sugimoto4, 1Dept of Internal Medicine, Kobe Century Memorial Hospital, Kobe, Japan, 2Department of Physiology and Regenerative Medicine, Kinki University Faculty of Medicine, Osakasayama, Japan, 3Internal Medicine 1, Shimane University Faculty of Medicine, Izmo, Japan, 4Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Bone turnover markers, glucocorticoids and osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Glucocorticoids (GCs) treatment induces secondary osteoporosis characterized by rapid bone loss and an increase in fracture risk, although GCs are used to treat a wide variety of rheumatic and autoimmune diseases. We have ever investigated the effects of GC therapy on bone metabolic indices and bone mineral density (BMD) in a prospective study. Our previous study indicated that the biochemical markers of bone metabolisim are affected from the early term of GC therapy (day3), and that the simultaneous treatment of alendronate (ALN) with GC therapy (co-dosage group) suppresses the changes of bone turnover markers at the early stage of GC therapy. Moreover, ALN was effective to suppress a reduction in BMD induced by GC. However, the simultaneous treatment of ALN was not effective to suppress an increase in bone resorption markers on day 7 of GC therapy and a reduction in BMD on 1 month. In the present study, we investigated the effects of pre-dosage ALN treatment before GC therapy on rapid bone loss in GC-treated patients prospectively.  

Methods: Twenty-one patients (62.0±9.9 y.o.) treated with prednisolone (PSL) at the dose of over 20 mg received weekly 35mg ALN one day or several days before the initiation of GC therapy (pre-dosage group), and serum Ca, intact parathyroid hormone (PTH), osteocalcin (OC), bone-type alkaline phosphatase (BAP) and urinary levels of type I collagen cross-linked N-telopeptide (NTx) were measured on 7 days, 1, 3 and 6 months after the initiation of GC therapy. BMD values were measured by dual-energy X-ray absorptiometory at the lumbar spine (L2-4) and femoral neck on 1,3,6 and12 months. The subjects were divided into the following two groups; 10 patients receiving PSL at doses³a40mg/day (H) and 11 patients receiving PSL at doses ³a20mg/day (M). 

Results: The pre-dosage ALN treatment caused decreases in serum Ca levels and urinary Ca excretion as well as a significant increase in serum PTH levels (p<0.05) on day 7 of GC treatment, which were not observed in the co-dosage group of our previous study. As for bone-formation indices, serum BAP levels were significantly decreased after 1 month only in the pre-dosage group, although serum OC levels were decreased on day 7 of GC administration in both co-dosage and pre-dosage groups. Although ALN was not effective to suppress an increase in bone resorption markers on day 7 of GC therapy in the co-dosage group, ALN decreased urinary NTx levels in the pre-dosage group. Moreover, BMD at lumbar spine were not decreased at 1 month and significantly increased 6 months after the initiation of GC therapy in the pre-dosage group, although ALN was not effective to suppress a reduction in BMD at 1 month in the co-dosage group. No significant reduction of BMD at femoral neck was observed in the pre-dose group. These results were similar in the subgroup analysis dividing into H and M groups.

Conclusion: The present study suggests that pre-dosage ALN treatment before GC therapy is more effective for the preservation of GC-induced osteoporosis, which might be attributed by early suppression of GC-stimulated bone resorption.


Disclosure:

Y. Kuroki,
None;

H. Kaji,
None;

M. Yamauchi,
None;

T. Sugimoto,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-pre-dosage-alendronate-treatment-on-bone-metabolic-indices-and-bone-mineral-density-in-patients-treated-with-glucocorticoids-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology